Search research articles
Contact Us
Filters
Showing results (111-120 of 120) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 120 results.
Chemico-Biological Interactions
|
August 28, 2018
Deoxypodophyllotoxin in Anthriscus sylvestris alleviates fat accumulation in the liver via AMP-activated protein kinase, impeding SREBP-1c signal
Kwang-Youn Kim, Kwang-Il Park, Seul Gi Lee, et al.
Gastroenterology
|
March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.
Open Forum Infectious Diseases
|
March 17, 2022
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
Anca Streinu-Cercel, Oana Săndulescu, Liliana-Lucia Preotescu, et al.
Journal of Korean Medical Science
|
December 8, 2017
Lead, Mercury, and Cadmium Exposure in the Korean General Population
Sang Yong Eom, Young Sub Lee, Seul Gi Lee, et al.
Chemico-Biological Interactions
|
December 6, 2016
Liqustri lucidi Fructus inhibits hepatic injury and functions as an antioxidant by activation of AMP-activated protein kinase in vivo and in vitro
Hye Lim Seo, Su Youn Baek, Eun Hye Lee, et al.
Inflammatory Bowel Diseases
|
April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies
Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Rheumatology (Oxford, England)
|
November 24, 2020
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
Rene Westhovens, Piotr Wiland, Marek Zawadzki, et al.
Clinical Therapeutics
|
September 23, 2021
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
Jin Yong Kim, Young Rock Jang, Jang Hee Hong, et al.
Open Forum Infectious Diseases
|
August 31, 2022
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Jin Yong Kim, Oana Săndulescu, Liliana-Lucia Preotescu, et al.
Nature Communications
|
February 19, 2024
PIBF1 regulates trophoblast syncytialization and promotes cardiovascular development
Jong Geol Lee, Jung-Min Yon, Globinna Kim, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 120) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 120 results.
Chemico-Biological Interactions
|
August 28, 2018
Deoxypodophyllotoxin in Anthriscus sylvestris alleviates fat accumulation in the liver via AMP-activated protein kinase, impeding SREBP-1c signal
Kwang-Youn Kim, Kwang-Il Park, Seul Gi Lee, et al.
Gastroenterology
|
March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.
Open Forum Infectious Diseases
|
March 17, 2022
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
Anca Streinu-Cercel, Oana Săndulescu, Liliana-Lucia Preotescu, et al.
Journal of Korean Medical Science
|
December 8, 2017
Lead, Mercury, and Cadmium Exposure in the Korean General Population
Sang Yong Eom, Young Sub Lee, Seul Gi Lee, et al.
Chemico-Biological Interactions
|
December 6, 2016
Liqustri lucidi Fructus inhibits hepatic injury and functions as an antioxidant by activation of AMP-activated protein kinase in vivo and in vitro
Hye Lim Seo, Su Youn Baek, Eun Hye Lee, et al.
Inflammatory Bowel Diseases
|
April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies
Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Rheumatology (Oxford, England)
|
November 24, 2020
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
Rene Westhovens, Piotr Wiland, Marek Zawadzki, et al.
Clinical Therapeutics
|
September 23, 2021
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
Jin Yong Kim, Young Rock Jang, Jang Hee Hong, et al.
Open Forum Infectious Diseases
|
August 31, 2022
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Jin Yong Kim, Oana Săndulescu, Liliana-Lucia Preotescu, et al.
Nature Communications
|
February 19, 2024
PIBF1 regulates trophoblast syncytialization and promotes cardiovascular development
Jong Geol Lee, Jung-Min Yon, Globinna Kim, et al.
Page
of 12